Boryung Pharmaceutical is about to expand to the Asian market with ‘Kanarb’
It is known that the Boryung Pharmaceutical’s self-developed new hypertension treatment, ‘Kanarb,’ will soon be advanced to the Asian market.
According to the industry concerned on the 12th, Boryung Pharmaceutical has decided to target a number of Asian countries, excluding China and Japan, via ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
